Dextromoramide

Identification

Name
Dextromoramide
Accession Number
DB01529
Description

An opioid analgesic structurally related to methadone and used in the treatment of severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1070)

Type
Small Molecule
Groups
Experimental, Illicit
Structure
Thumb
Weight
Average: 392.543
Monoisotopic: 392.246378278
Chemical Formula
C25H32N2O2
Synonyms
  • (+)-1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine
  • (+)-4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl)morpholine
  • 1-((3S)-3-methyl-4-(4-morpholinyl)-1-oxo-2,2-diphenylbutyl)pyrrolidine
  • 4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl)morpholine
  • D-2,2-diphenyl-3-methyl-4-morpholinobutyrylpyrrolidine
  • dextromoramida
  • Dextromoramide
  • dextromoramidum
  • palphium
  • Pyrrolamidol
External IDs
  • ACSCN-9613
  • IDS-ND-003
  • MCP-875
  • R-875
  • SKF-5137

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Dextromoramide.
AcetophenazineThe risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Dextromoramide.
AclidiniumThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Agomelatine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dextromoramide.
AlimemazineThe risk or severity of hypotension and CNS depression can be increased when Alimemazine is combined with Dextromoramide.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Dextromoramide.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Dextromoramide.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Dextromoramide.
AlprazolamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Alprazolam.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

International/Other Brands
palfium

Categories

ATC Codes
N02AC01 — Dextromoramide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenylacetamides / Phenylpropanes / N-acylpyrrolidines / Aralkylamines / Morpholines / Tertiary carboxylic acid amides / Trialkylamines / Amino acids and derivatives / Oxacyclic compounds / Dialkyl ethers
show 5 more
Substituents
Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Dialkyl ether / Diphenylmethane
show 19 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
N-acylpyrrolidine, morpholines (CHEBI:74274)

Chemical Identifiers

UNII
9S4S6CIY83
CAS number
357-56-2
InChI Key
INUNXTSAACVKJS-OAQYLSRUSA-N
InChI
InChI=1S/C25H32N2O2/c1-21(20-26-16-18-29-19-17-26)25(22-10-4-2-5-11-22,23-12-6-3-7-13-23)24(28)27-14-8-9-15-27/h2-7,10-13,21H,8-9,14-20H2,1H3/t21-/m1/s1
IUPAC Name
(3S)-3-methyl-4-(morpholin-4-yl)-2,2-diphenyl-1-(pyrrolidin-1-yl)butan-1-one
SMILES
C[[email protected]](CN1CCOCC1)C(C(=O)N1CCCC1)(C1=CC=CC=C1)C1=CC=CC=C1

References

General References
Not Available
KEGG Drug
D07287
PubChem Compound
92943
PubChem Substance
46507896
ChemSpider
83901
RxNav
3290
ChEBI
74274
ChEMBL
CHEMBL2365707
ZINC
ZINC000029402224
Wikipedia
Dextromoramide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)182 °CPhysProp
logP3.61SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0175 mg/mLALOGPS
logP4.17ALOGPS
logP3.75ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)7.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.78 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity117.37 m3·mol-1ChemAxon
Polarizability44.36 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.986
Caco-2 permeable+0.5628
P-glycoprotein substrateSubstrate0.6229
P-glycoprotein inhibitor IInhibitor0.6781
P-glycoprotein inhibitor IINon-inhibitor0.573
Renal organic cation transporterInhibitor0.525
CYP450 2C9 substrateNon-substrate0.8056
CYP450 2D6 substrateNon-substrate0.7581
CYP450 3A4 substrateSubstrate0.6149
CYP450 1A2 substrateNon-inhibitor0.9177
CYP450 2C9 inhibitorNon-inhibitor0.9297
CYP450 2D6 inhibitorInhibitor0.5
CYP450 2C19 inhibitorNon-inhibitor0.6691
CYP450 3A4 inhibitorNon-inhibitor0.6655
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7777
Ames testNon AMES toxic0.801
CarcinogenicityNon-carcinogens0.919
BiodegradationNot ready biodegradable0.9549
Rat acute toxicity3.7072 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8914
hERG inhibition (predictor II)Non-inhibitor0.6829
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on July 31, 2007 07:10 / Updated on June 12, 2020 10:51

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates